Global Healthcare Study on Psoriasis (GHSP)
2026年6月2日 更新者：Julia Tatjana Maul
The Global Healthcare Study on Psoriasis (GHSP) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis.
The study collects standardized clinical data from routine medical records to identify disparities in healthcare delivery and outcomes across different healthcare systems.
研究概览
地位
招聘中
条件
详细说明
The study employs a combined retrospective and prospective design, collecting data from routine clinical care and medical records spanning from January 2020 through the study conclusion.
研究类型
观察性的
注册 (估计的)
9600
联系人和位置
本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。
学习联系方式
- 姓名：Julia-Tatjana Maul
- 电话号码：+41 76 441 51 09
- 邮箱：julia-tatjana.maul@uzh.ch
研究联系人备份
- 姓名：Johannes A Didaskalu, Prof. Dr. med.
- 电话号码：+41 76 36 19 475
- 邮箱：johannes.didaskalu@uzh.ch
学习地点
-
-
-
Zurich、瑞士
- 招聘中
- University of Zurich
-
接触：
- Julia-Tatjana Maul
- 电话号码：+41 76 441 51 09
- 邮箱：julia-tatjana.maul@uzh.ch
-
-
参与标准
研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 孩子
- 成人
- 年长者
接受健康志愿者
不
取样方法
非概率样本
研究人群
Patient populations across world regions seen for psoriasis.
描述
Inclusion Criteria:
- Signed General Consent Form, or equivalent document
- Confirmed diagnosis of Psoriasis
Exclusion Criteria:
- Inability to provide informed consent.
- Datasets with ambiguous or unclear diagnosis.
学习计划
本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
|---|
|
Global Healthcare Study on Psoriasis
Patients with Psoriasis
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Psoriasis Area Severity Index (PASI)
大体时间：Baseline and follow-up visits every 6-12 months for up to 5 years.
|
Composite clinician-assessed measure of psoriasis severity based on erythema, scaling, thickness, and affected body surface area; total score ranges from 0 to 72, with higher scores indicating more severe disease.
|
Baseline and follow-up visits every 6-12 months for up to 5 years.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Dermatology Life Quality Index (DLQI)
大体时间：Baseline and follow-up visits every 6-12 months for up to 5 years.
|
Patient-reported measure of dermatology-specific quality of life; total score ranges from 0 to 30, with higher scores indicating greater impairment.
|
Baseline and follow-up visits every 6-12 months for up to 5 years.
|
|
Nail Psoriasis Severity Index (NAPSI)
大体时间：Baseline and follow-up visits every 6-12 months for up to 5 years.
|
Clinician-assessed measure of nail psoriasis severity based on nail matrix and nail bed involvement; scores range from 0-80 for fingernails and 0-80 for toenails; total score ranges from 0-160, with higher scores indicating more severe nail disease.
|
Baseline and follow-up visits every 6-12 months for up to 5 years.
|
|
Numerical Rating Scale (NRS) for disease severity
大体时间：Baseline and follow-up visits every 6-12 months for up to 5 years.
|
Patient-reported assessment of psoriasis severity on a numerical rating scale from 0 (no disease) to 10 (most severe disease imaginable).
|
Baseline and follow-up visits every 6-12 months for up to 5 years.
|
|
Physician Global Assessment (PGA)
大体时间：Baseline and follow-up visits every 6-12 months for up to 5 years.
|
Clinician-assessed global measure of psoriasis severity on a scale from 0 (clear) to 4 (severe).
|
Baseline and follow-up visits every 6-12 months for up to 5 years.
|
|
Body Surface Area (BSA)
大体时间：Baseline and follow-up visits every 6-12 months for up to 5 years.
|
Percentage of total body surface area affected by psoriasis, ranging from 0% to 100%.
|
Baseline and follow-up visits every 6-12 months for up to 5 years.
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员：Julia-Tatjana Maul, Prof. Dr. med.、University of Zurich
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Maul JT, Maul LV, Didaskalu JA, Valenzuela F, Romiti R, Peterson H, Korouri E, Novoa F, Oon HH, Zheng M, Wu JJ, Thyssen JP, Egeberg A, Armstrong AW, Nielsen ML. Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in Patients with Psoriasis: A Cross-sectional Global Healthcare Study on Psoriasis. Acta Derm Venereol. 2024 Mar 12;104:adv20329. doi: 10.2340/actadv.v104.20329.
- Valenzuela F, De La Cruz C, Lecaros C, Fernandez J, Hevia G, Maul LV, Thyssen JP, Vera-Kellet C, Egeberg A, Armijo D, Pizarro C, Riveros T, Correa H, Guglielmetti A, Didaskalu JA, Wu JJ, Griffiths CEM, Romiti R, Maul JT. Comorbidities in Chilean patients with psoriasis: a Global Healthcare Study on Psoriasis. Clin Exp Dermatol. 2022 Dec;47(12):2234-2241. doi: 10.1111/ced.15384. Epub 2022 Oct 28.
- Maul JT, Frohlich F, Maul LV, Stunnenberg R, Valenzuela F, De La Cruz C, Vera-Kellet C, Armijo D, Cesar WG, Carvalho A, Didaskalu JA, Graf N, Egeberg A, Wu JJ, Thyssen JP, Romiti R, Griffiths CEM. Access to psoriasis treatment in Brazil and Chile: A cross-sectional multicentre Global Healthcare Study on Psoriasis. Br J Dermatol. 2023 Mar 30;188(4):533-541. doi: 10.1093/bjd/ljac128.
- Korouri E, Jeong C, Peterson H, Valenzuela F, Romiti R, Didaskalu JA, Egeberg A, Oon HH, Maul LV, Kingston P, Lee K, Huang MY, Yee D, Artiga K, Aguero R, Maul JT, Armstrong AW. Global Comparison of COVID-19 Vaccination Rates among Psoriasis Patients. Life (Basel). 2024 Oct 13;14(10):1297. doi: 10.3390/life14101297.
- Goh E, Nielsen ML, Maul LV, Didaskalu JA, Chularojanamontri L, Guevara BEK, Ji M, Zheng M, Maul JT, Oon HH. Clinical Characteristics and Treatment Patterns of Psoriasis in Asia and Switzerland: Results of the Multicentre Global Healthcare Study on Psoriasis (GHSP). Int J Dermatol. 2026 Jun;65(6):1195-1202. doi: 10.1111/ijd.70183. Epub 2025 Nov 30.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2025年1月1日
初级完成 (估计的)
2029年12月31日
研究完成 (估计的)
2029年12月31日
研究注册日期
首次提交
2026年6月2日
首先提交符合 QC 标准的
2026年6月2日
首次发布 (实际的)
2026年6月8日
研究记录更新
最后更新发布 (实际的)
2026年6月8日
上次提交的符合 QC 标准的更新
2026年6月2日
最后验证
2026年6月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.